Characteristics and long-term survival of patients diagnosed with pure tubular carcinoma of the breast
Corresponding Author
Éric Poirier MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Correspondence
Éric Poirier, MD, FRCSC, Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec, 1050 chemin Ste-Foy, Quebec City, QC, Canada.
Email: [email protected]
Search for more papers by this authorChristine Desbiens MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorBrigitte Poirier MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorDominique Boudreau MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorSimon Jacob MD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de biologie moléculaire, biochimie médicale et pathologie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Service de Pathologie, Hôpital du St-Sacrement, CHU de Québec, Quebec City, QC, Canada
Search for more papers by this authorJulie Lemieux MD, MSc, FRCPC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Médecine, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Centre universitaire d'hématologie et d'oncologie de Québec, Quebec City, QC, Canada
Search for more papers by this authorCatherine Doyle MD, FRCPC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Médecine, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Centre universitaire d'hématologie et d'oncologie de Québec, Quebec City, QC, Canada
Search for more papers by this authorCaroline Diorio PhD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Search for more papers by this authorJean-Charles Hogue PhD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Search for more papers by this authorLouise Provencher MD, MA, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorCorresponding Author
Éric Poirier MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Correspondence
Éric Poirier, MD, FRCSC, Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec, 1050 chemin Ste-Foy, Quebec City, QC, Canada.
Email: [email protected]
Search for more papers by this authorChristine Desbiens MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorBrigitte Poirier MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorDominique Boudreau MD, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorSimon Jacob MD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de biologie moléculaire, biochimie médicale et pathologie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Service de Pathologie, Hôpital du St-Sacrement, CHU de Québec, Quebec City, QC, Canada
Search for more papers by this authorJulie Lemieux MD, MSc, FRCPC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Médecine, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Centre universitaire d'hématologie et d'oncologie de Québec, Quebec City, QC, Canada
Search for more papers by this authorCatherine Doyle MD, FRCPC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Médecine, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Centre universitaire d'hématologie et d'oncologie de Québec, Quebec City, QC, Canada
Search for more papers by this authorCaroline Diorio PhD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Search for more papers by this authorJean-Charles Hogue PhD
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Search for more papers by this authorLouise Provencher MD, MA, FRCSC
Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, CHU de Québec − Université Laval, Quebec City, QC, Canada
Axe Oncologie, Centre de Recherche du CHU de Québec − Université Laval, Quebec City, QC, Canada
Département de Chirurgie, Université Laval, Pavillon Ferdinand-Vandry, Quebec City, QC, Canada
Search for more papers by this authorAbstract
Background and Objectives
Pure tubular carcinomas (TC) of the breast are generally considered to have an excellent prognosis. This study aimed to analyze the characteristics and survival of patients with TC.
Methods
This was a retrospective study conducted at the CHU de Québec—Université Laval. Databases were searched for all cases treated between April 1997 and December 2010. Survival was retrieved from the Province of Quebec Ministry of Health. Follow-up was censored on December 31, 2011. Overall survival (OS) was compared to patients with invasive ductal carcinoma (ICD) matched for age, tumor size, lymph node involvement, year of diagnosis, ER, PgR, and HER2, histological grade, lymphovascular invasion, and chemotherapy.
Results
The frequency of TC was 2.9% (n = 223/7563). Tumors size was 7.4 ± 8.8 mm, without lymphovascular invasion (95.1%), ER-positive (98.2%), PgR-positive (69.5%), and HER2-negative (100%). Patients were followed up for 7.1 ± 2.7 years. The actuarial 13-year OS was 89.0% for TC, compared to 85.8% for IDC (P = 0.13). For TC, the 13-year OS was 95.8% in NO patients compared to 90.0% for N1-3 (P = 0.01).
Conclusion
Despite the general popular belief that patients with TC fare better than patients with IDC, the 13-year OS of TC was similar to that of grade I IDC.
CONFLICTS OF INTEREST
All authors declare no conflict of interest with the work presented in this manuscript.
REFERENCES
- 1 Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med. 2003; 163: 2149–2153.
- 2 Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer. 2005; 93: 1046–1052.
- 3 Stalsberg H, Thomas DB. Age distribution of histologic types of breast carcinoma. Int J Cancer. 1993; 54: 1–7.
- 4 Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 2004; 13: 1128–1135.
- 5NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) - Breast Cancer, version 1.2017. Fort Washington, National Comprehensive Cancer Network.
- 6 Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347: 1233–1241.
- 7 Veronesi U, Salvadori B, Luini A, et al. Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomized trials on 1,973 patients. Eur J Cancer. 1995; 31A: 1574–1579.
- 8 Winchester DJ, Sahin AA, Tucker SL, Singletary SE. Tubular carcinoma of the breast. Predicting axillary nodal metastases and recurrence. Ann Surg. 1996; 223: 342–347.
- 9 Lagios MD, Rose MR, Margolin FR. Tubular carcinoma of the breast: association with multicentricity, bilaterality, and family history of mammary carcinoma. Am J Clin Pathol. 1980; 73: 25–30.
- 10 Holland DW, Boucher LD, Mortimer JE. Tubular breast cancer experience at Washington University: a review of the literature. Clin Breast Cancer. 2001; 2: 210–214.
- 11 Liu GF, Yang Q, Haffty BG, Moran MS. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2009; 75: 1304–1308.
- 12 Carstens PH. Tubular carcinoma of the breast. A study of frequency. Am J Clin Pathol. 1978; 70: 204–210.
- 13
Cooper HS,
Patchefsky AS,
Krall RA. Tubular carcinoma of the breast.
Cancer.
1978;
42: 2334––2342.
10.1002/1097-0142(197811)42:5<2334::AID-CNCR2820420534>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 14 Oberman HA, Fidler WJ, Jr. Tubular carcinoma of the breast. Am J Surg Pathol. 1979; 3: 387–395.
- 15 Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast. Clinical pathologic correlations based on 100 cases. Ann Surg. 1981; 193: 138–149.
- 16 Deos PH, Norris HJ. Well-differentiated (tubular) carcinoma of the breast. A clinicopathologic study of 145 pure and mixed cases. Am J Clin Pathol. 1982; 78: 1–7.
- 17
Taylor HB,
Norris HJ. Well-differentiated carcinoma of the breast.
Cancer.
1970;
25: 687–692.
10.1002/1097-0142(197003)25:3<687::AID-CNCR2820250328>3.0.CO;2-J CAS PubMed Web of Science® Google Scholar
- 18 Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys. 2004; 59: 152–159.
- 19 Gunhan-Bilgen I, Oktay A. Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. Eur J Radiol. 2007; 61: 158–162.
- 20 Lea V, Gluch L, Kennedy CW, et al. Tubular carcinoma of the breast: axillary involvement and prognostic factors. ANZ J Surg. 2015; 85: 448–451.
- 21 Min Y, Bae SY, Lee HC, et al. Tubular carcinoma of the breast: clinicopathologic features and survival outcome compared with ductal carcinoma in situ. J Breast Cancer. 2013; 16: 404–409.
- 22 Hansen CJ, Kenny L, Lakhani SR, et al. Tubular breast carcinoma: an argument against treatment de-escalation. J Med Imaging Radiat Oncol. 2012; 56: 116–122.
- 23 Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010; 28: 99–104.
- 24 Vo T, Xing Y, Meric-Bernstam F, et al. Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007; 194: 527–531.
- 25 Sullivan T, Raad RA, Goldberg S, et al. Tubular carcinoma of the breast: a retrospective analysis and review of the literature. Breast Cancer Res Treat. 2005; 93: 199–205.
- 26 Papadatos G, Rangan AM, Psarianos T, et al. Probability of axillary node involvement in patients with tubular carcinoma of the breast. Br J Surg. 2001; 88: 860–864.
- 27 Javid SH, Smith BL, Mayer E, et al. Tubular carcinoma of the breast: results of a large contemporary series. Am J Surg. 2009; 197: 674–677.
- 28 Cabral AH, Recine M, Paramo JC, et al. Tubular carcinoma of the breast: an institutional experience and review of the literature. Breast J. 2003; 9: 298–301.
- 29 Livi L, Paiar F, Meldolesi E, et al. Tubular carcinoma of the breast: outcome and loco-regional recurrence in 307 patients. Eur J Surg Oncol. 2005; 31: 9–12.
- 30 Kitchen PR, Smith TH, Henderson MA, et al. Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg. 2001; 71: 27–31.
- 31 Kader HA, Jackson J, Mates D, et al. Tubular carcinoma of the breast: a population-based study of nodal metastases at presentation and of patterns of relapse. Breast J. 2001; 7: 8–13.
- 32 Diab SG, Clark GM, Osborne CK, et al. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999; 17: 1442–1448.
- 33 Li B, Chen M, Nori D, et al. Adjuvant radiation therapy and survival for pure tubular breast carcinoma-experience from the SEER database. Int J Radiat Oncol Biol Phys. 2012; 84: 23–29.
- 34 Parl FF, Richardson LD. The histologic and biologic spectrum of tubular carcinoma of the breast. Hum Pathol. 1983; 14: 694–698.
